# A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

> **NCT06409195** · PHASE2 · RECRUITING · sponsor: **DermBiont, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Non-Melanoma Skin Cancers

## Interventions

- **DRUG:** SM-020 1% Gel

## Key facts

- **NCT ID:** NCT06409195
- **Lead sponsor:** DermBiont, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409195, "A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06409195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*